Siirry sisältöön

Sirppisolutauti (lapset)

Anemian hoito

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (avaa uuden ikkunan)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Lähde‎: Lancet Haematol. 2023 ;10(4):e261-71.

Arkistoitu‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (avaa uuden ikkunan)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (avaa uuden ikkunan)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Lähde‎: Acta Haematol 1995;94(3):128-34.

Arkistoitu‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (avaa uuden ikkunan)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (avaa uuden ikkunan)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Lähde‎: Haematologica 2006;91(8):1076-83.

Arkistoitu‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (avaa uuden ikkunan)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (avaa uuden ikkunan)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Lähde‎: J Obstet Gynaecol 2007;27(1):82-3.

Arkistoitu‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (avaa uuden ikkunan)